FRTX — Fresh Tracks Therapeutics Share News
0.000.00%
Last trade - 00:00- $5.59m
- -$5.28m
- $8.01m
Brief: Brickell Biotech Completes Patient Enrollment In Phase 3 Study Of Sofpironium Bromide Gel To Treat Primary Axillary Hyperhidrosis
Brief: Brickell Biotech Reports Results From U.S. Phase 3 Open-Label, Long-Term Safety Study On Chronic Use Of Sofpironium Bromide Gel As A Potential Treatment For Primary Axillary Hyperhidrosis
Brief: Brickell Biotech Announces Publication Of HDSM-AX Patient Reported Outcome Scale Validation Results In The Journal Of Drugs In Dermatology
Brief: Brickell Biotech Files For Common Stock Offering Of Up To $50 Mln
Brief: Brickell Biotech Reports Fourth Quarter And Full Year 2020 Financial Results
Brief: Brickell Biotech Inc Files For Mixed Shelf Of Upto $150 Million - SEC Filing
Brief: Brickell Biotech Inc Says Received Letter From Nasdaq Notifying Company That It Had Regained Compliance
Brief: Brickell Biotech Announces Publication Of Japan Pivotal Phase 3 Study Results For Sofpironium Bromide Gel, 5% In The Journal Of Dermatology
Brief: Brickell Biotech Doses First Patient In Second U.S. Pivotal Phase 3 Clinical Study
Brief: Brickell Biotech Inc - R. Michael Carruthers, CFO And Principal Accounting Officer, Will Be Resigning
Brief: Brickell Biotech Inc - Kaken Plans To Launch ECCLOCK For Treatment Of Primary Axillary Hyperhidrosis In Japan On November 26, 2020
Brief: Brickell Biotech Reports Q3 Revenue Of $100,000
U.S. STOCKS ON THE MOVE-American Express, Gilead, Socket Mobile, Uber
Brickell Biotech: Falls on at-par stock offering
Brief: Brickell Biotech Announces Pricing Of $15.0 Mln Underwritten Public Offering
Brickell Biotech: Up on launching late-stage U.S. trial of excess sweat therapy
Brief: Brickell Biotech Announces Initiation Of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel 15% For Treatment Of Primary Axillary Hyperhidrosis
U.S. STOCKS ON THE MOVE-Prelude Therapeutics, Carnival Corp, CalAmp Corp, VIA Optronics AG
U.S. STOCKS ON THE MOVE-Marinus Pharmaceuticals, Trip.com, Schlumberger, Goldman Sachs